Children's Drug Shortage Industry-University-Research Cooperation Helps Children's Drug Research and Development


Release time:

2015-07-08


On June 30, the "Children's Drug Research and Development" strategic seminar co-sponsored by the Institute of Materia Medica, Chinese Academy of Medical Sciences and Shandong Dain Marine Biopharmaceutical Co., Ltd. was held in Beijing. The meeting focused on hot issues such as the development direction of children's medication and the development of key technologies for new preparations for children's medication, and exchanged views on solving various problems in children's medication. A number of experts at the meeting suggested that the research and development of children's drugs should combine production, teaching and research to jointly help the development of the industry.
Research and development of children's medicine should be supported by industry, university and research.
Many experts said that we should rely on the cooperation of industry, university and research to support the research and development of pediatric drugs. Academician Zhan Qimin, vice president of Peking Union Medical College, Chinese Academy of Medical Sciences, believes that many problems endanger the safety of children's medication. As a special group, children are still in the stage of growth and development, and their absorption and excretion of drugs are different from those of adults. More research and policy support for children's medication should be strengthened.
Academician Chen Xiangmei, director of the Department of Nephrology of the PLA General Hospital, believes that children often have higher requirements for drugs, but my country's current research and development of children's drugs is seriously lacking. It is called for speeding up the solution of the problems such as the lack of suitable varieties of children's drugs, the lack of suitable dosage forms and specifications, and the lag in the research and development of children's drugs, and more exchanges and discussions in order to better promote the research and development of children's drugs.
Dai Yaohua, a doctoral supervisor and researcher at the Capital Institute of Pediatrics, told reporters that because children's organs and body functions are in the process of continuous growth, maturity and improvement, the absorption, distribution, metabolism and excretion of drugs are very different from those of adults. Therefore, it is very important to choose appropriate drugs, dosage forms and dosages for children. Some diseases that are prone to high incidence among children have a stronger demand for the development of corresponding drugs.
Professor Zheng Wensheng believes that the state should establish supporting policies to encourage the research, development and production of children's drugs, such as setting up a special children's drug research fund to provide technical guidance for children's drug research and development, review and approval, setting up a market monopoly period or extension period, and giving tax relief and other industrial support policies to children's drug production enterprises. It is suggested that the research and development of children's drugs should be encouraged from the aspects of pricing mechanism, medical insurance system, bidding procurement, tax system, review and approval, so as to enhance the motivation of enterprises to develop and produce children's drugs.
Jiang Jiandong, director of the Institute of Materia Medica of the Chinese Academy of Medical Sciences, pointed out that under the framework of strategic cooperation signed between the Institute of Materia Medica of the Academy of Medical Sciences and Dain Pharmaceutical, the joint holding of a strategic seminar on the research and development of drugs for children is a very timely and important academic activity to promote the research and development of drugs for children in China under the new situation of the country's vigorous advocacy of industry-university-university-research and research and research and research.
Tailoring is the responsibility and mission of the enterprise
Due to the special needs of children, children's medicines are more demanding than adult medicines. In this regard, Yang Jie, chairman of the Children's Medication Professional Committee of the China Pharmaceutical Enterprise Management Association and general manager of Dyne Pharmaceuticals, said that as a pharmaceutical company, the urgent task is to study Tailor-made children's medicines, figure out what varieties are in short supply for children, and then conduct pharmaceutical research on different dosage forms, specifications and tastes for children of different ages, and improve clinical data. Only by tailoring can the safety, effectiveness and compliance of children's medication be guaranteed.
Yang Jie revealed that according to the research and development concept of tailor-made drugs for children, the company has determined clear research and development ideas: first, the research work of improving taste, enriching dosage forms and perfecting specifications for domestic listed drugs; Secondly, we will carry out the localization of foreign drugs. Furthermore, we will carry out the original innovation work and carry out the research and development of children's drugs with independent intellectual property rights.
Children's health represents the national medical and health level, which is related to the quality of the population and social harmony. The development and production of children-specific drugs is a cause of great social value and imagination. Yang Jie said, "Youth wisdom is the country's wisdom, youth wealth is the country's wealth, youth strength is the country's strength", children's health is the unremitting pursuit of dyne pharmaceutical.
The spring of medicine is coming.
In recent years, in order to improve the current situation of the shortage of drugs for children in China, government departments have issued a series of supporting policies, especially in May 2014, six ministries and commissions, including the National Development and Reform Commission and the Health and Family Planning Commission, issued "some opinions on ensuring the use of drugs for Children." to provide favorable policies for the evaluation and research and development of children's drugs. In March this year, the National Health and Family Planning Commission's Children's Drug Expert Committee was established and held its first plenary meeting in May. In May this year, the Children's Medication Professional Committee of the China Pharmaceutical Enterprise Management Association was established and held its first working meeting.
At the end of the meeting, Jiang Jiandong, director of the Institute of Medicine of the Chinese Academy of Medical Sciences, and Yang Jie, chairman of the Children's Medication Professional Committee of the China Pharmaceutical Enterprise Management Association and general manager of Dain Pharmaceutical, signed a cooperation agreement on children's special drug research and development projects on behalf of both sides under the framework of the existing strategic cooperation agreement. Through the signing of this R & D project cooperation agreement, we will give full play to the main role of enterprises in technological innovation and the advantages of pharmaceutical research institutes in terms of technical talents, break through the technical bottleneck in the development of industrialization, accelerate the transformation of innovative achievements, promote the healthy development of children's medication in China, and create a new mode of industry-university-research cooperation in children's medication in China.